Compare NNBR & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNBR | ABEO |
|---|---|---|
| Founded | 1980 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.7M | 282.5M |
| IPO Year | 1996 | 2005 |
| Metric | NNBR | ABEO |
|---|---|---|
| Price | $2.82 | $2.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $7.00 | ★ $15.56 |
| AVG Volume (30 Days) | ★ 2.2M | 2.1M |
| Earning Date | 10-28-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.60 | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $770,657,000.00 | $2,998,000.00 |
| Revenue This Year | $16.85 | $675.42 |
| Revenue Next Year | $7.19 | $126.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $1.10 | $2.09 |
| 52 Week High | $4.65 | $7.65 |
| Indicator | NNBR | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 38.54 | 30.01 |
| Support Level | $2.74 | N/A |
| Resistance Level | $3.06 | $5.77 |
| Average True Range (ATR) | 0.25 | 0.32 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 13.16 | 25.61 |
NN Inc is a diversified industrial company that combines engineering and production capabilities with materials science expertise to design and manufacture high-precision components and solutions. The company operates through two segments: Mobile Solutions, which generates maximum revenue and focuses on the automotive, general industrial, and medical end markets, manufacturing tight-tolerance components used in battery electric, hybrid electric, and internal combustion engine vehicles, braking, transmissions, fuel systems, HVAC, and diesel systems; and Power Solutions, which focuses on the electrical, general industrial, automotive, medical, and aerospace and defense end markets and manufactures high-precision metal components, assemblies, contact assemblies, and precision stampings.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.